|
|
| |
 |
By Sophie Gardner and Kelly Hooper |
Presented by |
 |
|
|
With help from Amanda Chu and Simon J. Levien
|
|
|
|

Montana residents have access to therapies in the early research stages through the state's right-to-try law. | Keith Srakocic/AP Photo |
BIOTECH FIRMS EYE MONTANA — Biotech investors are gaining a foothold in Montana as the state implements new rules that make it the most expansive in the country for accessing drugs unapproved by the Food and Drug Administration, Amanda reports with Business Insider’s Hilary Brueck and Welt’s Andreas Macho, whose outlets are both part of the Axel Springer Global Reporters Network, which includes POLITICO. Last year, Montana passed a law allowing individuals, regardless of their medical conditions, to access therapies that have completed Phase I clinical trials that show the product likely won’t harm patients, even if proven effectiveness isn't yet demonstrated. This marks a sharp departure from federal programs, including President Donald Trump’s right-to-try law in his first term, which require patients to be terminally ill and to have exhausted all FDA-approved treatments and clinical trial options. Startup biotech firms hope Montana will serve as their shortcut around the FDA’s costly and extensive drug-development process, arguing the state could mark the start of a new right-to-try model that prioritizes patient access over paternalistic government oversight. Meanwhile, some patient advocates fear the state has put hucksters in charge of medical decisions. Industry influence: The biotech industry has shaped the Montana program since its inception, helping draft bill provisions and testifying during state deliberations. Now, Montana is relying on a privately run board to decide which treatments are offered — raising concerns about conflicts of interest and, in an industry rife with unfounded claims, whether patients will get value for their money. Infinita, a company that works with biotech firms in a regulation-free zone off the coast of Honduras, is overseeing the process. Its chief executive, Niklas Anzinger, a 37-year-old German investor, has set up the only review board so far, charging a $12,500 application fee to companies seeking to sell experimental treatments in Montana. The board approved its first treatment last month. Stephen Martin, who leads U.S. initiatives at Infinita and manages intake for the Montana review board, said board members must disclose any conflicts each time they review an application and that none have occurred so far. Elephant in the room: The success of Montana’s biotech experiment hinges on whether the FDA will crack down on companies operating in Montana, an uncertainty that has stymied other state right-to-try efforts. The biotech industry has reason to hope: Health and Human Services Secretary Robert F. Kennedy Jr. has pledged to increase access to longevity treatments. Last year, he said he had traveled to Antigua to receive a non-FDA-approved stem cell treatment for a neurological condition that affects his voice. In June, Infinita, biotech companies and patient advocates met with FDA officials, including Deputy Commissioner Grace Graham, to ask for a guarantee that the agency wouldn’t take action against them in Montana. Attendees said they haven’t received a direct answer. An FDA spokesperson declined to comment. WELCOME TO TUESDAY PULSE. Sen. Mitch McConnell (R-Ky.) has returned to the Capitol this week, ending a three-month health-related absence. Send your tips, scoops and feedback to khooper@politico.com and sgardner@politico.com, and follow along @kelhoops and @sophie_gardnerJ.
|
| |
A message from the Coalition to Strengthen America’s Healthcare: How many more cuts to care can patients take? Funding cuts can impact patient access to hospitals and health systems through longer waits, fewer services, and closures that could scale back the 24/7 care their communities rely on. Tell Congress to reject cuts and protect timely access to hospital care when patients need it most. Tell Congress: Protect America’s Patients |
| |
|
|
|
|
|

Sen. Bill Cassidy is eager to revise the No Surprises Act before he leaves office. | J. Scott Applewhite/AP Photo |
NO SURPRISES SESSIONS — The Senate Health Committee will hold a series of stakeholder roundtables today to consider changes to the No Surprises Act that shielded patients from unexpected bills for out-of-network emergency care, Simon reports. Committee staff will hold listening sessions with providers, patient groups, employers and insurers — and hold a separate meeting with independent arbitrators, who by law resolve disputes between doctors and insurers over who has to pick up those medical bills. “It’s just like Festivus,” a person familiar with the committee’s plans and granted anonymity told POLITICO, comparing the roundtable to the fictional holiday. “We’re going to pass the stick and air our grievances about this.” But the committee is a long way from introducing a bill that would address complaints of huge payouts and lopsided arbitration. Session participants on Tuesday are not expecting to see a discussion draft. Another source familiar with the committee’s plans said that staff is framing the discussion around two questions: What’s the most important policy change you would like to see, and what would you compromise to reach a workable solution? “That kind of questioning will bring us together,” the person said. Chair Bill Cassidy (R-La.), who has only a few months left in office, is steaming ahead with revisions to the 2020 law he helped craft. The committee will hold a member roundtable to talk solutions next week, according to a committee spokesperson. No Surprises reforms and a bill his committee approved to make hospital prices more transparent have become key parts of Cassidy’s health-policy swan song. The other committees that could legislate on the No Surprises Act are farther behind. The House Ways and Means Committee is holding fact-finding meetings on the topic, and the House Energy and Commerce Committee is still brainstorming solutions, according to the person familiar with the plans as well as a second person also familiar with the planning. HEARING WATCH — Chris Klomp is set to appear for his confirmation hearing this week, as he seeks the No. 2 role at HHS. He’ll testify before the Senate Finance Committee today and the Health, Education, Labor and Pensions Committee on Wednesday. Klomp has overseen all Department of Health and Human Services operations since February, as part of a leadership shakeup in which he was promoted and former Deputy Secretary Jim O’Neill was ousted, POLITICO’s Carmen Paun reports. Only Finance will decide whether to advance his nomination to a full Senate floor vote. Trump has touted Klomp’s success in getting the world’s biggest drug companies to ink deals with his administration to lower their prices and to invest more in U.S. manufacturing as evidence of Klomp’s prowess as a negotiator. Democrats say the administration’s refusal to disclose the deals’ terms suggests they aren’t as great as advertised. They plan to make the case at the hearing, a Senate Democratic aide granted anonymity to speak candidly told POLITICO. Democrats are also expected to question Klomp about the ongoing measles outbreak, which has reached nearly 3,300 reported cases — a 35-year high. Pennsylvania has reported three recent measles-related deaths, two of which led to a showdown between Kennedy and the state’s Democratic Gov. Josh Shapiro. “Klomp is going to be the No. 2, and he bears a lot of operational responsibility for how the agency is handling that,” the Democratic aide said.
|
| |
Spencer Cox on America’s political divide In the latest episode of On the Road, Jonathan Martin sits down with Utah Gov. Spencer Cox to discuss his new book, Off Ramp, the future of the Republican Party, immigration reform and what he says it will take to rebuild trust and community in American life.
Watch now. |
| |
| |
|
|
|
HOSPITAL GROUP LAUNCHES AD — A coalition backed by the largest hospital trade associations released a new ad Tuesday warning lawmakers about the impact of upcoming cuts to Medicaid, Amanda reports. The national 30-second ad from the Coalition to Strengthen America’s Healthcare, which counts the American Hospital Association and the Federation of American Hospitals on its board, is part of the group’s seven-figure ad campaign launched earlier this year. The ad, which will run digitally and on television, highlights how upcoming cuts to Medicaid could leave hospitals with billions in additional costs and force them to close their doors. Big picture: The ad arrives as lawmakers on both sides of the aisle ramp up scrutiny of hospitals and other major players in the health care industry over their role in the high cost of care ahead of the midterms. The hospital industry is ramping up another lobbying blitz to mitigate the impact of the One Big Beautiful Bill Act, last year’s Republican reconciliation package that included nearly $1 trillion in Medicaid cuts. Hospitals say that recent proposed rules from the Trump administration would make those cuts go further than Congress intended.
|
| |
A message from the Coalition to Strengthen America’s Healthcare: 
|
| |
|
|
|
|
BABY FORMULA SETTLEMENT — Abbott Laboratories has agreed to pay more than $384 million to resolve a case over potentially contaminated infant formula, which the Department of Justice alleges the company sold to government programs, POLITICO’s Marcia Brown reports. The DOJ filed the civil suit against Abbott last year over claims stemming from the shutdown of its Sturgis, Michigan, plant in 2022 after the Food and Drug Administration initiated a recall of several of its infant formula brands due to possible contamination with the bacteria Cronobacter. FDA inspectors found significant safety violations at the plant, and the DOJ argued in its complaint that the company, one of the nation’s largest infant formula manufacturers, knew the plant had environmental contaminants. Abbott agreed to settle the claims without admitting or denying the DOJ allegations.
|
| |
Canberra Playbook Your morning read on Australian federal politics. Canberra Playbook: clear, impartial and free every weekday before the working day starts. Subscribe free.
Subscribe Now. |
| |
| |
|
|
|
Blue Cross Blue Shield Association, a federation of locally operated health insurance companies, has named Dan Serrano senior vice president and chief financial officer. He was previously chief financial officer at ABA Centers of America. The Healthcare Distribution Alliance, a group that advocates for healthcare distribution companies, has announced that Debbie Weitzman, CEO of pharmaceutical and specialty solutions at Cardinal Health, was elected chair of the association’s board of directors. Rick Seipp, president and CEO of Value Drug Company, will serve as vice chair.
|
|
|
NBC News’ Erika Edwards reports on how a Pennsylvania woman’s death is underscoring that the disease can pose a health risk to adults with underlying conditions. STAT News’ Daniel Payne reports that hospital leaders say the GOP’s $50 billion rural health fund is coming up short.
|
| |
A message from the Coalition to Strengthen America’s Healthcare: How many more cuts to care can patients take?
Hospitals and health systems provide 24/7 quality care to everyone who needs it, but they're being forced to absorb billions in unpaid care while facing continued funding cuts from Washington.
More cuts don't just hurt balance sheets — they impact patients, in the form of longer wait times, reduced services, and hospital closures that could leave entire communities without nearby care.
Congress must reject cuts because America’s patients deserve 24/7 quality hospital care.
Tell Congress: Protect America’s Patients |
| |
|
|
| |
Follow us on X
|
| |
Follow us
|
| |
|
0 Comments